The U.S. Food and Drug Administration has approved Merck's new oral medication, Lipfendra, designed to significantly lower cholesterol levels. This marks the first non-injectable drug that targets the PCSK9 protein, a mechanism previously only accessible through expensive and often restricted injectable treatments. Clinical trials demonstrated substantial reductions in LDL cholesterol, with patients experiencing over 55% decrease after six months when Lipfendra was added to their existing statin therapy. AI
RANK_REASON FDA approval of a novel drug class represents a significant development in medical treatment. [lever_c_demoted from significant: ic=1 ai=0.0]
- Amgen
- Dr. Marty Makary
- Howard Hughes Medical Institute
- Lipfendra
- PCSK9
- Rahway
- Robert Wood Johnson Foundation
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
